GILD
GILEAD SCIENCES, INC.
- PER (TTM)
- 17.87
- PER (Forward)
- 13.65
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 7.18
- 시가총액
- 163.06B
- 배당수익률
- 250.00%
- 베타
- 0.33
- 1개월 수익률
- -7.57%
- 3개월 수익률
- -13.39%
- 6개월 수익률
- 8.46%
- 1년 수익률
- 36.32%
- 2년 수익률
- -
- 5일 평균거래량
- 7507060
- 60일 평균거래량
- 6284363
- 1년 평균거래량
- 7108526
- 5d/60d 거래량 비율
- 1.19×
- 60d/1y 거래량 비율
- 0.88×
- 변동성(60일, 연환산)
- 22.32%
- BB 스퀴즈 스코어
- 1.17
- SMA50 비율
- 0.95
- SMA200 비율
- 1.04
- RSI (14)
- 42
- 20일 수렴도
- 0.03
- 52주 최고
- 154.92
- 52주 최저
- 94.40
- 고점 대비
- -15.23%
- 저점 대비
- 39.12%
펀더멘털 갱신: 2026-05-10T09:10:56+00:00 · 시세 갱신: 2026-05-10T06:37:02+00:00
회사 정보
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.